Fast-acting treatment for postpartum depression, if approved, could help hundreds of thousands of new mothers

Marie McCausland gave birth to a baby boy, Jeffrey, on Mother’s Day of 2017.

Postpartum depression affects one in nine women in the U.S., according to the Centers for Disease Control and Prevention. Symptoms include feeling sad or tearful, suicidal thoughts, inability to take pleasure in things that were once pleasurable, inability to concentrate and a change in sleep patterns. It is associated with worse nutrition and health in the newborn and can interfere with breast-feeding and mother-infant bonding. It can happen during or after a pregnancy.

Developed by Sage Therapeutics Inc. SAGE, +2.18% which plans to market the drug under the name Zulresso, it would be the first drug therapy approved to specifically treat postpartum depression. The main component of the brexanolone injection is allopregnanolone, a progesterone metabolite that binds to gamma-aminobutyric acid receptors in the brain which play a role in regulating mood. The amount of allopregnanolone in the body increases during pregnancy and then falls rapidly after childbirth.

Also: As Kate Middleton’s brother opens up about his depression, here’s why talking about mental health helps The main side effects of the drug were headache, dizziness and sleepiness. One patient lost consciousness during the infusion, but regained it when the infusion was turned down.

If it’s not meditation or yoga.... SideEffectsSuck BigPharma

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Nation’s cancer chief appointed acting FDA commissionerNorman 'Ned' Sharpless has been named acting head of the Food and Drug Administration. he's off the cancer reservation now I hope he approves of CBD in food and beverages cronyism at work.
Source: washingtonpost - 🏆 95. / 72 Read more »